Opus Genetics Shareholders Approve Governance and Capital Changes

Opus Genetics ( (IRD) ) just unveiled an update.

At its April 20, 2026 annual meeting, Opus Genetics, Inc. stockholders elected nine directors to one-year terms, ratified Ernst & Young, LLP as independent auditor for the 2026 fiscal year, and approved on an advisory basis the compensation of the company’s named executive officers. Investors also backed a charter amendment doubling authorized common shares from 125 million to 250 million, a move that expands the company’s flexibility for future equity issuance, potential capital raising, and strategic initiatives, while reinforcing existing governance and executive pay practices through solid shareholder support.

These outcomes indicate continued investor confidence in the current leadership team and financial oversight, as shown by strong votes in favor of all proposals, including the auditor ratification and say-on-pay resolutions. The substantial increase in authorized share capital may have implications for future dilution but positions Opus Genetics to access additional funding and pursue growth or partnership opportunities, signaling a more expansive capital markets strategy going forward.

The most recent analyst rating on (IRD) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Opus Genetics stock, see the IRD Stock Forecast page.

Spark’s Take on IRD Stock

According to Spark, TipRanks’ AI Analyst, IRD is a Neutral.

The score is primarily held back by deteriorating financial performance (declining revenue, large losses, and accelerating cash burn). Partially offsetting this are constructive price momentum signals and positive corporate events that improve liquidity/runway, while valuation remains constrained by unprofitability and the absence of dividend support.

To see Spark’s full report on IRD stock, click here.

More about Opus Genetics

Opus Genetics, Inc. operates in the biopharmaceutical sector, focusing on genetic medicines and therapies, with its equity widely held by public stockholders and overseen by a multi-member board of directors. The company’s governance framework includes annual election of directors, independent auditing, and shareholder oversight of executive compensation and capital structure decisions.

Average Trading Volume: 970,080

Technical Sentiment Signal: Hold

Current Market Cap: $394.2M

See more data about IRD stock on TipRanks’ Stock Analysis page.